Buscopan Compositum Solution for Injection

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Butylscopolamine bromide, Metamizole

Διαθέσιμο από:

Boehringer Ingelheim Ltd

Φαρμακολογική κατηγορία (ATC):

QA03DB04

INN (Διεθνής Όνομα):

Butylscopolamine bromide, Metamizole

Δοσολογία:

Not Currently Available

Φαρμακοτεχνική μορφή:

Solution for injection

Τρόπος διάθεσης:

POM: Prescription Only Medicine as defined in relevant national legislation

Θεραπευτική ομάδα:

Cattle, Dogs, Horses

Θεραπευτική περιοχή:

butylscopolamine and analgesics

Θεραπευτικές ενδείξεις:

N.S.A.I.D.

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

1991-10-01

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Buscopan Compositum Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
A slightly yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (adult), horses and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
As an aid in the control of pain associated with simple equine colic
and as a diagnostic aid in more severe equine
colics.
For the control of diarrhoea in cattle, horses and dogs particularly
when pain or abdominal discomfort is present.
For the control of pain associated with urinary obstruction in horses
and dogs.
4.3 CONTRAINDICATIONS
Due to a risk of local reactions do not use the intramuscular route in
horses.
Do not use in animals with known hypersensitivity to the active
ingredients.
Do not use in horses suffering from paralytic ileus.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Each ml contains:
ACTIVE SUBSTANCE
Butylscopolamine bromide
4 mg
Metamizole
500 mg
EXCIPIENTS
Phenol (as preservative)
5 mg
For a full list of excipients, see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_0_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_8_
_5_
_7_
_6_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMAL